RESUMO
Studies utilizing the administration of GnRH in various GnRH-deficient models have revealed the critical importance of the dose and mode of delivery of this releasing factor in determining the subsequent pituitary response. Chronic administration of long acting GnRH agonists (GnRHa), like continuous infusion of high doses of the native peptide, results in suppression of pituitary gonadotropin secretion. This selective and reversible suppression of gonadotropin secretion suggested several therapeutic applications for these analogs, particularly in the treatment of central precocious puberty (CPP), a disorder for which the previously available therapies lacked uniform efficacy and were associated with potential side effects. In our series, 74 children with CPP have been treated during the last 5 yr with the potent GnRH agonist, [D-Trp6, Pro9-ethylamide(NEt)]GnRH. Having selected a dose and route of administration that produced uniform suppression of spontaneous and stimulated pituitary gonadotropin secretion, GnRHa therapy resulted in a fall of gonadal sex steroid levels into the prepubertal range, a halting or regression of secondary sexual development, and a complete cessation of menses. Growth velocity slowed during therapy, with this slowing more pronounced during prolonged treatment periods and among those patients with more advanced chronological and skeletal ages. Skeletal maturation was retarded to a greater degree than linear growth, with resultant increases in the predictions for adult stature. Moreover, these benefits have been achieved in the absence of significant side effects. Complete reversal of the suppression of gonadarche has followed discontinuation of therapy; however, patterns of growth and skeletal maturation after discontinuation of GnRHa administration remain to be characterized. Thus, the impact of GnRHa therapy on final height must await further longitudinal study. The selective nature of GnRHa suppression of gonadarche also permits an investigation of the natural history of adrenarche and its discrete influences upon skeletal growth and maturation. In addition, GnRHa therapy of CPP provides a unique opportunity to study the effects of gonadal sex steroids on GH secretion and somatomedin-C (Sm-C) generation during sexual maturation. Finally, the detailed characterization of children with precocious puberty has helped to define more precisely a subset of patients whose precocity occurs in the absence of demonstrable gonadotropin secretion.(ABSTRACT TRUNCATED AT 400 WORDS)
Assuntos
Hormônio Liberador de Gonadotropina/análogos & derivados , Puberdade Precoce/tratamento farmacológico , Pamoato de Triptorrelina/análogos & derivados , Glândulas Suprarrenais/fisiologia , Hiperplasia Suprarrenal Congênita/complicações , Desenvolvimento Ósseo , Criança , Pré-Escolar , Desidroepiandrosterona/análogos & derivados , Desidroepiandrosterona/sangue , Sulfato de Desidroepiandrosterona , Estradiol/sangue , Feminino , Hormônio Liberador de Gonadotropina/administração & dosagem , Hormônio Liberador de Gonadotropina/efeitos adversos , Hormônio Liberador de Gonadotropina/uso terapêutico , Hormônio do Crescimento/metabolismo , Hamartoma/complicações , Humanos , Neoplasias Hipotalâmicas/complicações , Fator de Crescimento Insulin-Like I/metabolismo , Hormônio Luteinizante/metabolismo , Masculino , Hormônios Liberadores de Hormônios Hipofisários/metabolismo , Hormônios Liberadores de Hormônios Hipofisários/fisiologia , Puberdade Precoce/etiologia , Puberdade Precoce/fisiopatologia , Testosterona/sangueRESUMO
Suppression of gonadal sex steroid secretion in children with central precocious puberty (CPP) by LHRH analogs affords an opportunity to study sex steroid modulation of GH and somatomedin-C (Sm-C) secretion and to examine the role of GH and Sm-C in pubertal and prepubertal statural growth. Nocturnal serum GH and plasma Sm-C levels were measured in 10 preadrenarchal girls [mean age, 3.0 +/- 0.6] ( +/- SEM) yr with CPP before and during 2 yr of LHRH analog-induced gonadal suppression. Their mean height velocity, initially 4.6 +/- 0.6 ( +/- SEM) SD above the mean for chronological age, decreased to -0.1 +/- 0.4 SD during 12-24 months of ovarian suppression (P less than 0.00005). The mean peak nocturnal plasma GH level was 22.5 +/- 5.4 ( +/- SEM) micrograms/L during puberty, and it decreased to 10.2 +/- 2.1 micrograms/L after 3 months of suppression of gonadarche. This decrease persisted throughout the 2 yr of gonadal suppression (P less than 0.05). The reduction in GH secretion was accompanied by a decrease in mean plasma Sm-C levels from 3.5 +/- 0.7 to 1.5 +/- 0.2 U/mL after 3 months of suppression of gonadal sex steroids, which persisted during 2 yr of gonadal suppression (P less than 0.01). Suppression of ovarian function in girls with CPP results in decreased height velocity. This slowing of growth occurs in association with decreased nocturnal serum GH and plasma Sm-C levels, suggesting that acceleration of growth during puberty is partially mediated by sex steroid-induced augmentation of GH secretion.
Assuntos
Hormônios Esteroides Gonadais/metabolismo , Hormônio Liberador de Gonadotropina/análogos & derivados , Hormônio do Crescimento/sangue , Fator de Crescimento Insulin-Like I/sangue , Ovário/fisiopatologia , Puberdade Precoce/tratamento farmacológico , Somatomedinas/sangue , Pamoato de Triptorrelina/análogos & derivados , Determinação da Idade pelo Esqueleto , Estatura , Peso Corporal , Desenvolvimento Ósseo , Pré-Escolar , Desidroepiandrosterona/análogos & derivados , Desidroepiandrosterona/sangue , Sulfato de Desidroepiandrosterona , Feminino , Hormônio Liberador de Gonadotropina/farmacologia , Hormônio Liberador de Gonadotropina/uso terapêutico , Humanos , Lactente , Ovário/efeitos dos fármacos , Hipófise/fisiopatologia , Puberdade Precoce/fisiopatologiaRESUMO
Thirteen patients with type 1 glycogen-storage disease (GSD-1) were studied to compare the effects on biochemical control and growth of 2 y of therapy with intermittent feedings of uncooked cornstarch (UCS) at the fasting glucose production rate and therapy with continuous overnight glucose (COG) and dextrose feedings during the day. Mean biochemical abnormalities for the groups were minimized but not normalized by either COG or UCS. Growth progressed normally when COG was started by 1.2 y of age and normal growth rate was maintained by UCS. Weight increased from 101 +/- 3% ideal body weight at onset of COG to 127 +/- 5% during COG and the first year of UCS therapy but did not increase further in the second year. When growth failure occurred before onset of COG [-3.7 SD score for chronological age (SDSCA)], only partial correction (-1.9 SDSCA) to genetic potential for height occurred. Intermittent feeding of UCS provides an effective alternative to COG for the treatment of GSD-1.
Assuntos
Glucose/administração & dosagem , Doença de Depósito de Glicogênio Tipo I/fisiopatologia , Amido/administração & dosagem , Adolescente , Glicemia/análise , Estatura , Peso Corporal , Criança , Pré-Escolar , Colesterol/sangue , Feminino , Doença de Depósito de Glicogênio Tipo I/sangue , Hormônio do Crescimento/sangue , Humanos , Hidrocortisona/sangue , Insulina/sangue , Lactatos/sangue , Estudos Longitudinais , Masculino , Estudos Prospectivos , Triglicerídeos/sangue , Ácido Úrico/sangueRESUMO
Traditional two-dimensional (2-D) growth charts do not distinguish between the effects of a particular pathology or therapy on skeletal maturation and the effects on linear growth. In this study, longitudinal data from two growth studies on children were analysed using a computer technique to produce a growth chart in three dimensions. The three-dimensional (3-D) surface of the graph represents both the linear growth and the skeletal maturation of the patients. If the height and the chronological and bone ages of an individual patient are plotted to give a line in 3-D space, the line can be compared with the 3-D surface of the graph. This permits qualitative assessment of the relative effect of a pathology or treatment on skeletal maturation as compared with linear growth. Quantitative assessment is also possible by expressing the data in polar coordinates. The technique can be applied to clinical trials as well as to individual patients.
Assuntos
Estatura/fisiologia , Crescimento , Computação Matemática , Adolescente , Criança , Pré-Escolar , Humanos , Lactente , Estudos LongitudinaisRESUMO
Sixty-nine growth hormone-deficient patients were treated for 1 year with somatotropin (recombinant DNA-derived human growth hormone) produced in mouse cells. The growth velocity of the 50 patients (72%) in whom the effectiveness of this growth hormone could be evaluated increased from a mean (+/- SD) of 3.5 +/- 1.1 to 8.7 +/- 1.6. cm/y. An enhanced rate of weight gain was also observed. Bone age was not unduly accelerated. One of 66 patients developed antibodies to recombinant growth hormone, which did not affect the response to therapy. No patient developed antibodies to host cell proteins. An increased insulin response to a standard glucose load, without any change in glucose tolerance, was observed after 1 year of treatment. This authentic sequence human growth hormone preparation produced in mammalian cells is both effective and safe in the treatment of children with growth hormone deficiency.